Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Rich-Vicks (up 3-3/8 to 40) was the biggest point gainer on the "F-D-C" Index during the week ended Sept. 6, after rumors emerged on the "Street" late last week concerning a buyout of the company -- by either American Cyanamid or Unilever. Despite Cyanamid's denial that it had made an offer, Rich-Vicks stock was traded heavily, with volume reaching nearly 675,000 shares on Friday. The company refused to comment on the unusual activity. Investors reacted favorably to Avon's (up 2-1/8 to 24) announcement that it would sell its Mallinckrodt unit and use the proceeds, which could amount to $500 mil., to buy back up to 25% of its outstanding common stock (see related story). Syntex (up 2-1/2 to 63) showed a strong northward move after the company announced that its fourth quarter earnings leaped 65%. Overall, health-related issues did not fare well, as the Composite dropped a little more than a point over the week, compared to a similar rise for the Dow average, which finished at 1335. Losers out numbered gainers on the lndex 30 to 18, with three issues remaining unchanged. Chain stocks were the biggest component losers, with only two of 10 companies showing gains. American Stores (down 2 to 56-1/8) declined after announcing flat second quarter earnings. Chart omitted.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts